Skip to: Content
Skip to: Site Navigation
Skip to: Search

SUNDAY, NOVEMBER 8, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter

PREMIUM NEWS ARCHIVE

Cougar Biotechnology Announces Presentation of Positive CB7630 Abiraterone Acetate Phase II Data at ASCO 2009 Genitourinary Cancers Symposium.(Clinical report)

Article from: Blood Weekly Article date: March 19, 2009

Cougar Biotechnology, Inc. (NASDAQ: CGRB) announced that results from ongoing Phase II clinical trials of CougarEs investigational drug CB7630 (abiraterone acetate) were presented at the ASCO Genitourinary Cancers Symposium that is currently taking place in Orlando, Florida. The data were presented today in two poster presentations. These presentations are further detailed below: Abiraterone Acetate Plus Prednisone in Chemotherapy Naive Castration Resistant Prostate Cancer (CRPC) Patients Not Exposed to Ketoconazole: Results of ...

Read full article   (with a Free Trial at HighBeam Research)
Newser gathers stories from across the web and packs what you need to know into about 120 words. Check out these stories related to your search.
Visit our grid for the latest news.